In this study, we demonstrated the anti-fibrotic effect of ADSCs on LFs from IPF patients through PTPRR upregulation, which inhibits ERK1/2 phosphorylation. The gene discussed is MAPK3; the disease is idiopathic pulmonary fibrosis.